Bis(phenazine-1-carboxamides): Structure−Activity Relationships for a New Class of Dual Topoisomerase I/II-Directed Anticancer Drugs
- 15 March 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (7) , 1350-1358
- https://doi.org/10.1021/jm990423f
Abstract
Ring-substituted bis(phenazine-1-carboxamides), linked by a −(CH2)3NMe(CH2)3− chain, were prepared from the corresponding substituted phenazine-1-carboxylic acids by reaction of the intermediate imidazolides with bis(3-aminopropyl)methylamine. The compounds were evaluated for growth inhibitory activity in a panel of tumor cell lines, including P388 leukemia, Lewis lung carcinoma, and wild-type (JLC) and mutant (JLA and JLD) forms of human Jurkat leukemia. The latter mutant lines are resistant to topoisomerase (topo) II targeted agents because of lower levels of the enzyme. Analogues with small, lipophilic substituents (e.g., Me, Cl) at the 9-position were the most potent inhibitors, superior to the corresponding dimeric bis(acridine-4-carboxamides) (bis-DACA analogues). Several of the compounds were preferentially (up to 2-fold) more cytotoxic toward the mutant Jurkat lines than the wild-type. To test whether this selectivity was related to topoisomerase action, the most potent of the compounds (9-methyl) was evaluated in a cell-free system. It poisoned topo I at drug concentrations of 0.25 and 0.5 μM and inhibited the catalytic activity of both topo I and topo II at concentrations of 1 and 5 μM, respectively. Results from the NCI human tumor cell line panel showed the compounds had preferential activity toward colon tumor lines (on average 9.5-fold more active in the HT29 line than in the cell line panel as a whole). Several analogues produced significant growth delays in the relatively refractory subcutaneous colon 38 tumor model in vivo. In particular, the 9-methyl compound was substantially more potent in this tumor model than the clinical dual topo I/II poison DACA (total dose 90 versus 400 mg/kg) with comparable activity. The bis(phenazine-1-carboxamides) are a new and interesting class of dual topo I/II-directed anticancer drugs.Keywords
This publication has 11 references indexed in Scilit:
- Structure−Activity Relationships for Substituted Bis(acridine-4-carboxamides): A New Class of Anticancer AgentsJournal of Medicinal Chemistry, 1999
- Chromophore-Modified Bis-Naphthalimides: Synthesis and Antitumor Activity of Bis-Dibenz[de,h]isoquinoline-1,3-dionesJournal of Medicinal Chemistry, 1997
- Sequence‐Selective Intercalation of Antitumour Bis‐Naphthalimides into DNAEuropean Journal of Biochemistry, 1996
- From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): Selectivity for topoisomerases I and II among acridine derivativesEuropean Journal Of Cancer, 1996
- Experimental solid tumour activity ofN-[2-(dimethylamino)ethyl]-acridine-4-carboxamideCancer Chemotherapy and Pharmacology, 1995
- Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancersCancer Chemotherapy and Pharmacology, 1994
- Microculture-Based Chemosensitivity Testing: A Feasibility Study Comparing Freshly Explanted Human Melanoma Cells With Human Melanoma Cell LinesJNCI Journal of the National Cancer Institute, 1992
- Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell LinesJNCI Journal of the National Cancer Institute, 1991
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990
- Multiple Patterns of Resistance of Human Leukemia Cell Sublines to Amsacrine AnaloguesJNCI Journal of the National Cancer Institute, 1990